文献速递前列腺癌

Movember基金会GAP3队列:迄今最大全球前列腺癌主动监测数据库概况

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date.
PubMed 文献 · BJU Int · 2018-01-18

该数据库旨在为主动监测的选择与监测建立全球共识。

要点

  • 诊断时中位年龄65岁,中位PSA 5.4 ng/mL,多数为cT1期、Gleason 6分。
  • 5年、10年、15年仍在主动监测的比例分别为58%、39%、23%。

核心结论

  • GAP3是迄今最大的全球前列腺癌主动监测协作数据库,其结果有助于患者和临床医生对延迟或进行主动治疗做出更有信心的个体化决策。

研究设计与样本

  • 采用描述性统计报告诊断时临床和人口学特征、临床随访、主动监测终止及后续治疗,采用累积发生率曲线报告随时间终止率。

主要发现

  • 诊断时中位(IQR)年龄为65(60-70)岁,中位PSA为5.4(4.0-7.3)ng/mL。
  • 多数患者为临床T1期(71.8%)、活检Gleason评分6分(88.8%)和1个肿瘤阳性活检核心(60.3%)。
  • 主动监测患者中位随访时间为2.2(1.0-5.0)年。
  • 随访5年、10年和15年时,仍在主动监测的患者比例分别为58%、39%和23%。

关键数值与推荐

  • 当前版本GAP3对磁共振成像(MRI)、生活质量和基因组检测的数据有限。

临床怎么用

  • GAP3结果将让个体患者和临床医生对延迟或进行主动治疗的个体化决策有更大信心。
  • 更长的随访以及对MRI、新基因组标志物和患者相关结局的评估将产生更有价值的数据,并最终改善患者结局。

局限性

  • 当前版本GAP3对MRI、生活质量和基因组检测的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bruinsma SM, Zhang L, Roobol MJ, et al. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int. 2018. PMID: 29247473. doi:10.1111/bju.14106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。